These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22421142)

  • 1. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.
    Ye F; Lattif AA; Xie J; Weinberg A; Gao S
    Cell Cycle; 2012 Apr; 11(7):1393-9. PubMed ID: 22421142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth.
    Yu X; Sha J; Xiang S; Qin S; Conrad P; Ghosh SK; Weinberg A; Ye F
    Cell Cycle; 2016 Aug; 15(15):2053-65. PubMed ID: 27294705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
    Sarek G; Kurki S; Enbäck J; Iotzova G; Haas J; Laakkonen P; Laiho M; Ojala PM
    J Clin Invest; 2007 Apr; 117(4):1019-28. PubMed ID: 17364023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.
    An FQ; Folarin HM; Compitello N; Roth J; Gerson SL; McCrae KR; Fakhari FD; Dittmer DP; Renne R
    J Virol; 2006 May; 80(10):4833-46. PubMed ID: 16641275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
    Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.
    Sharma-Walia N; Paul AG; Bottero V; Sadagopan S; Veettil MV; Kerur N; Chandran B
    PLoS Pathog; 2010 Feb; 6(2):e1000777. PubMed ID: 20169190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes.
    Curreli F; Friedman-Kien AE; Flore O
    J Clin Invest; 2005 Mar; 115(3):642-52. PubMed ID: 15765147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation.
    Angius F; Piras E; Uda S; Madeddu C; Serpe R; Bigi R; Chen W; Dittmer DP; Pompei R; Ingianni A
    J Antibiot (Tokyo); 2017 Aug; 70(9):962-966. PubMed ID: 28611469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
    Davaadelger B; Shen H; Maki CG
    PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.